Package Insert: Information for the Patient
TAVLESSE 100 mg Film-Coated Tablets
TAVLESSE 150 mg Film-Coated Tablets
fostamatinib disodium hexahydrate
Read this package insert carefully before starting to take this medicine, as it contains important information for you.
What is TAVLESSE
TAVLESSE contains the active ingredient fostamatinib. It specifically acts on an enzyme called spleen tyrosine kinase, which plays an important role in the destruction of platelets. In this way, TAVLESSE limits the destruction of platelets by the immune system and increases their number in the body. This helps to reduce the risk of severe bleeding.
What is TAVLESSE used for
TAVLESSE is used for the treatment of adults with low platelet counts due to chronic immune thrombocytopenia (ITP) when a previous ITP treatment has not been sufficiently effective. ITP is an autoimmune disease in which the body's own immune system attacks and destroys the platelets in the blood. Platelets are necessary to help create clots and stop bleeding.
Do not take TAVLESSE
Warnings and precautions
Consult your doctor or pharmacist before starting to take TAVLESSE about all your medical conditions, especially if:
Inform your doctor, pharmacist, or nurse immediately if you experience any of the following symptoms while taking this medication:
Children and adolescents
TAVLESSE should not be used in patients under 18 years old. TAVLESSE has not been studied in this age group.
Other medications and TAVLESSE
Inform your doctor or pharmacist if you are taking, have taken recently, or may take any other medication.
The taking of TAVLESSE with certain medications may affect the mechanism of action of other medications, and other medications may affect the mechanism of action of TAVLESSE. In particular, inform your doctor if you are taking any of the following medications:
Pregnancy, breastfeeding, and fertility
Pregnancy
TAVLESSE should not be used during pregnancy. It may cause damage or congenital defects to the fetus.
If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
If you are a woman and may become pregnant, you should use a reliable contraceptive method while taking TAVLESSE and continue to use it for at least one month after taking the last dose.
Contact your doctor immediately if you become pregnant while taking this medication.
Breastfeeding
It is not recommended to use TAVLESSE during breastfeeding. You should not breastfeed during treatment with TAVLESSE or for at least one month after the last dose.
If you are breastfeeding or plan to breastfeed, consult your doctor or pharmacist before using this medication.
Fertility
TAVLESSE may affect a woman's ability to become pregnant and have a child. Talk to your doctor if this concerns you. There is no effect on men.
TAVLESSE - contains sodium
[TAVLESSE 100 mg film-coated tablets]. This medication contains 23 mg of sodium (main component of table salt/for cooking) in each tablet. This is equivalent to 1.2% of the maximum daily sodium intake recommended for an adult.
[TAVLESSE 150 mg film-coated tablets]. This medication contains 34 mg of sodium (main component of table salt/for cooking) in each tablet. This is equivalent to 1.7% of the maximum daily sodium intake recommended for an adult.
How much to take
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Before starting treatment, your doctor will measure your platelet count.
The recommended dose of TAVLESSE is 100 mg twice a day (one 100 mg tablet).
However, your doctor will check your platelet count during treatment with TAVLESSE and may change your dose if necessary.
Once treatment with TAVLESSE has begun, the dose may be increased to 150 mg twice a day (one 150 mg tablet) based on platelet count and tolerability. Do not exceed a daily dose of 300 mg (two 150 mg tablets) per day.
If you do not respond to treatment with fostamatinib, your doctor will discontinue treatment
If you have liver problems or high blood pressure, your doctor may start treatment with a lower dose.
If you experience severe side effects (such as high blood pressure, liver problems, diarrhea, or a decrease in white blood cells), your doctor may reduce your dose or temporarily or permanently discontinue treatment.
How to take TAVLESSE
Swallow the tablets whole with water.
TAVLESSE can be taken with food or between meals.
If you have stomach discomfort, take the tablets with food.
If you vomit
If you vomit at any time after taking TAVLESSE, do not take an additional tablet. Take the next dose at the usual time.
If you take too much TAVLESSE
If you take too much TAVLESSE, immediately contact your doctor or pharmacist or go to the nearest hospital emergency department.
If you forget to take TAVLESSE
Do not take a double dose to make up for missed doses. Take the next dose at the usual time.
If you interrupt treatment with TAVLESSE
It is essential to take TAVLESSE as directed by your doctor. Do not stop taking this medication unless your doctor tells you to.
If you have any other questions about using this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Severe side effects
TAVLESSE can cause severe side effects. Inform your doctor immediately if you experience any of the following severe side effects, whether they occur for the first time or worsen (see also section 2):
Other side effects
In addition to the severe side effects mentioned earlier, you may experience other side effects.
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Reporting side effects
If you consider that any of the side effects you experience are severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist. You can also report them directly through thenational notification system included in theAppendix V.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
This medication does not require any special temperature for conservation. Store in the original packaging to protect it from moisture. Keep the bottle perfectly closed.
Do not use this medication after the expiration date that appears on the box and the bottle after CAD. The expiration date refers to the last day of the month indicated.
Medicines should not be thrown down the drain or in the trash. Ask your pharmacist how to dispose of the containers and the medications that you no longer need. In this way, you will help protect the environment.
Composition of TAVLESSE
TAVLESSE 100 mg film-coated tablets
TAVLESSE 150 mg film-coated tablets
Appearance of the product and contents of the pack
TAVLESSE 100 mg film-coated tablets
The film-coated tablet is round, curved on both sides, with a dark orange film. The tablets have the inscription «R» on one side and «100» on the other.
Available in bottles of 30 and 60 film-coated tablets. Each bottle contains 2 desiccants.
Only some pack sizes may be marketed.
TAVLESSE 150 mg film-coated tablets
The film-coated tablet is oval, curved on both sides, with a light orange film. The tablets have the inscription «R» on one side and «150» on the other.
Available in bottles of 30 and 60 film-coated tablets. Each bottle contains 2 desiccants.
Only some pack sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Instituto Grifols, S.A.
Can Guasc, 2 - Parets del Vallès
08150 Barcelona - Spain
For more information about this medicine, please contact the local representative of the marketing authorization holder:
AT/BE/BG/CY/EE/EL/ES/HR/HU/IE/LV/ LT/LU/MT/NL/RO/SI/SK Instituto Grifols, S.A. Tel: +34 93 571 01 00 | CZ Grifols S.R.O. Tel: +4202 2223 1415 |
DE Grifols Deutschland GmbH Tel: +49 69 660 593 100 | DK/FI/IS/NO/SE Grifols Nordic AB Tel: +46 8 441 89 50 |
FR Grifols France Tél: +33 (0)1 53 53 08 70 | IT Grifols Italia S.p.A. Tel: +39 050 8755 113 |
PL Grifols Polska Sp. z o. o. Tel: +48 22 378 85 60 | PT Grifols Portugal, Lda. Tel: +351 219 255 200 |
Last revision date of this leaflet:11/2024
For detailed information about this medicine, please visit the website of the European Medicines Agency:
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.